Vancomycin (VCM) and daptomycin (DAP) are standard therapies for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, despite concerns
This text and table is intended for use as a study tool to assist people learning pharmacology of agents used for vancomycin-resistant enterococci (VRE) infections in the acute care setting
Once in the body, they show Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E
We conducted a multicentre prospective cohort study to compare linezolid and daptomycin (≥6 mg/kg) for the treatment of VRE
Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia
e7
Meanwhile, daptomycin exerts bactericidal activity against VRE, but is not approved for the treatment of VRE bacteremia
A report of the treatment of vancomycin-resistant enterococcal (VRE) bacteremia showed that 30-day mortality of daptomycin was higher than that of linezolid
This study assessed the outcomes of patients with VRE-B treated with linezolid or daptomycin
7log 10 CFU/mL kill) and indifference (1
The in vitro activity of daptomycin against three VISA isolates was compared with that of vancomycin, linezolid, and Q–D
aureus infections requiring inpatient treatment include linezolid, daptomycin, and ceftaroline
Daptomycin is a cyclic lipopeptide antibiotic derived from the organism Streptomyces roseosporus
innocuum
Empiric intravenous linezolid was then initiated following preliminary positive blood cultures with Gram-positive cocci in clusters with positive MRSA PCR
Current data on the use of daptomycin in pediatric patients are limited
7 Likewise, linezolid had lower total costs compared with vancomycin and daptomycin therapy when efficacy rates